The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Salivary Cortisol Hypertension Assay

18 Dec 2015 09:43

RNS Number : 5543J
Immunodiagnostic Systems Hldgs PLC
18 December 2015
 

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

18 December 2015

 

Immunodiagnostic Systems Holdings plc.

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has launched the IDS-iSYS Salivary Cortisol assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The launch of the IDS-iSYS Salivary Cortisol assay enhances the IDS Hypertension panel, which also includes the automated IDS-iSYS Aldosterone and IDS-iSYS Direct Renin immunoassays.

The IDS-iSYS Salivary Cortisol assay measures a patient's salivary cortisol and offers clinicians an easy, non-invasive way to diagnose diseases of cortisol imbalance such as Cushing's Syndrome (CS). One sign of CS is a higher than expected level of cortisol, which can often lead to hypertension.

As the fastest salivary cortisol automated test on the market the IDS-iSYS Salivary Cortisol assay allows laboratories to benefit from a reduced time to first result.

The global market size of salivary cortisol testing is estimated to be around £5 - £10 million.

For further information:

Immunodiagnostic Systems Holdings plc Telephone: +44(0)191 519 0660Patricio Lacalle, CEOJaap Stuut, Marketing DirectorPeel Hunt LLP Telephone: +44(0)207 418 8900James Steel

 

About Immunodiagnostic Systems Holdings plc.:A Specialist in Endocrinology TestingImmunodiagnostic Systems Holdings plc (IDS) is a leading in vitro diagnostic solution provider to the clinical laboratory market. IDS develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. The IDS immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.

IDS was founded in 1977 and trades on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.IDS is a global company headquartered in the UK with around 400 employees worldwide. The group's products are developed and manufactured at their facilities in Europe. IDS serve customers through regional offices in Europe, U.S.A. and Brazil. The group's network of distributors work on IDS' behalf to serve customers throughout the rest of the world.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGCBDDDSBBGUI
Date   Source Headline
28th Jun 201612:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20161:42 pmRNSDirector/PDMR Shareholding
22nd Jun 20167:45 amRNSAnnual Report and Accounts
22nd Jun 20167:00 amRNSPreliminary Results
9th Jun 20167:00 amRNSUpdate re Royalty Revenues
20th May 20169:20 amRNSHolding(s) in Company
6th May 201610:30 amRNSLaunch of IDS-iSYS 17-OH Progesterone assay
25th Apr 20167:00 amRNSFull Year Trading Update
8th Jan 20167:00 amRNSRelocation of Automated related Assay Activity
4th Jan 20167:30 amRNSPaul Martin joins as Group Finance Director
18th Dec 20159:43 amRNSLaunch of Salivary Cortisol Hypertension Assay
30th Nov 201510:41 amRNSHolding(s) in Company
24th Nov 20157:00 amRNSHalf Yearly Report
22nd Oct 20152:22 pmRNSDirectorate Change
21st Oct 20155:00 pmRNSHolding(s) in Company - Replacement
20th Oct 20152:23 pmRNSDirectorate Change
13th Oct 20157:00 amRNSTrading Statement
8th Oct 20154:40 pmRNSHolding(s) in Company
1st Oct 201512:05 pmRNSTotal Voting Rights
30th Sep 20152:05 pmRNSHolding(s) in Company
15th Sep 20154:32 pmRNSAdditional Listing
4th Aug 20152:43 pmRNSResult of AGM
4th Aug 20157:00 amRNSAGM Statement
29th Jun 20153:18 pmRNSRe Report and Accounts and AGM - Replacement
29th Jun 201511:59 amRNSRe Report and Accounts and AGM
29th Jun 20157:15 amRNSDirectorate Change
23rd Jun 20157:00 amRNSFinal Results
12th Jun 20154:00 pmRNSBoard Appointment
10th Jun 20157:00 amRNSDirectorate Change
29th May 20157:00 amRNSTrading Statement
21st Apr 20157:00 amRNSTrading Statement
2nd Apr 20157:43 amRNSPatricio Lacalle Joins as Chief Executive Officer
9th Feb 201510:30 amRNSHolding(s) in Company
3rd Feb 20157:00 amRNSDirectorate Change
6th Jan 20155:04 pmRNSAdditional Listing
5th Jan 20155:10 pmRNSAdditional Listing
24th Dec 20141:30 pmRNSDirectorate Change
19th Dec 201410:47 amRNSHolding(s) in Company
19th Dec 20148:40 amRNSHolding(s) in Company
18th Dec 20149:30 amRNSDirector/PDMR Shareholding
15th Dec 20145:13 pmRNSHolding(s) in Company
12th Dec 20147:00 amRNSLaunch of 1,25-Dihydroxy Vitamin D Assay
8th Dec 20143:38 pmRNSHolding(s) in Company
4th Dec 20145:36 pmRNSDirectorate Change
4th Dec 20144:27 pmRNSDirector/PDMR Shareholding
25th Nov 20147:00 amRNSDirectorate Change
25th Nov 20147:00 amRNSHalf Yearly Report
24th Nov 20145:20 pmRNSPatrik Dahlen Resigns as CEO
14th Oct 20147:00 amRNSTrading Update
15th Sep 20147:00 amRNSUpdate on current trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.